Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 24Fallopian Tube Neoplasms 20Breast Neoplasms 10Carcinoma, Ovarian Epithelial 8Sarcoma 6Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Sarcoma, Kaposi 2Sarcoma, Ewing 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Multi-centric Castleman's Disease 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leiomyosarcoma 2Hodgkin Disease 2Burkitt Lymphoma 2Acquired Immunodeficiency Syndrome 2AIDS-related Kaposi sarcoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Uterine Cervical Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1

Interventions

Doxorubicin 5pembrolizumab 4Specimen Handling 4Radiotherapy 4Radiation 4Nivolumab 4Magnetic Resonance Spectroscopy 3Ipilimumab 3CTLA-4 Antigen 3Biopsy 3cabozantinib 2Ifosfamide 2tremelimumab 1talimogene laherparepvec 1regorafenib 1peposertib 1pazopanib 1olaratumab 1liposomal doxorubicin 1futibatinib 1fludarabine 1eribulin 1durvalumab 1avelumab 1aldesleukin 1X-Rays 1Trabectedin 1Standard of Care 1Quality of Life 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × liposomal doxorubicin × 1 year × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡